<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="130937">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01657877</url>
  </required_header>
  <id_info>
    <org_study_id>RH01381</org_study_id>
    <nct_id>NCT01657877</nct_id>
  </id_info>
  <brief_title>Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice</brief_title>
  <official_title>In Situ Study to Confirm the Anti-caries Potential of a 1.1365% w/w Sodium Monofluorophosphate (1500ppm F) Dentifrice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In situ study to compare treatment effect on enamel remineralization potential, measured by
      surface microhardness recovery (SMHR) and Enamel Fluoride Uptake (EFU). The study will
      explore the efficacy of an experimental sodium monofluorophosphate (SMFP) dentifrice
      containing calcium sodium phosphosilicate (CSP) in comparison to an experimental SMFP only
      dentifrice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage surface microhardness recovery (SMHR) of test dentifrice containing 1500 ppm fluoride as SMFP and 5 % w/w CSP relative to reference dentifrice containing 1500 ppm fluoride as SMFP and 0 % w/w CSP</measure>
    <time_frame>Baseline to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline (B), after in-situ hardening (R) and after first demineralization challenge (D1) using formula: [(D1-R)/ (D1-B)]*100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage SMHR of reference dentifrices containing 500 ppm fluoride as SMFP and 0 % w/w CSP, no fluoride as SMFP and no CSP, and no fluoride as SMFP and 5 % w/w CSP.</measure>
    <time_frame>Baseline to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>SMHR test was used to assess the changes in mineralization status of enamel specimens using a Wilson 2100 Hardness tester. SMHR was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening while decrease in the indentation length represents rehardening of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline (B), after in-situ hardening (R) and after first demineralization challenge (D1) using formula: [(D1-R)/ (D1-B)]*100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage enamel fluoride uptake (EFU)</measure>
    <time_frame>Baseline to 21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>EFU was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Caries</condition>
  <arm_group>
    <arm_group_label>CSP/SMFP Dentifrice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dentifrice containing high fluoride content as SMFP and CSP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMFP Dentifrice Prototype 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dentifrice containing high fluoride content as SMFP and no CSP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMFP Dentifrice Prototype 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dentifrice containing low fluoride content as SMFP and no CSP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CSP Dentifrice</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dentifrice containing CSP but no fluoride</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Dentifrice</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dentifrice containing no CSP and no fluoride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium sodium phosphosilicate</intervention_name>
    <description>CSP high percentage weight by weight</description>
    <arm_group_label>CSP/SMFP Dentifrice</arm_group_label>
    <arm_group_label>CSP Dentifrice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium monoflurophosphate</intervention_name>
    <description>500 to 1500 parts per million (ppm) of fluoride</description>
    <arm_group_label>SMFP Dentifrice Prototype 2</arm_group_label>
    <arm_group_label>CSP/SMFP Dentifrice</arm_group_label>
    <arm_group_label>SMFP Dentifrice Prototype 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>No CSP and no fluoride</description>
    <arm_group_label>Placebo Dentifrice</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Wears a removable bilateral mandibular partial denture that has good stability and
             support, with sufficient room on each side in the posterior buccal flange area to
             accommodate two enamel specimens [required dimensions 12 x 7 millimeters (mm)].
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University School of Dentistry</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 15, 2014</lastchanged_date>
  <firstreceived_date>August 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluorophosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
